Therefore, we specifically examined the effects of targeting the FAK-Src complex by addressing pFAK and pSrc expressions in clinical tumor sections of primary and post-treatment resections, metastatic and locally recurrent DSRCT (n = 13), ES (n = 68), and RMS (ARMS n = 21, ERMS n = 39) and by determining the antitumor effects of the combined treatment of the FAK inhibitor defactinib and the multikinase (Abl/SFK) inhibitor dasatinib in DSRCT, ES, ARMS, and ERMS cell lines. This evidence concerns the gene SRC and embryonal rhabdomyosarcoma.